Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Daan Gene Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Luo Huang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	2.4yrs

Son yönetim güncellemeleri

Recent updates

Daan Gene Co., Ltd. (SZSE:002030) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

Aug 20

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

May 02

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Apr 05

Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)

Mar 25

Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Mar 06

CEO

Luo Huang (44 yo)

2.3yrs

Görev süresi

CN¥5,967,200

Tazminat

Ms. Luo Huang is Non-Executive Director of Yunkang Group Limited from August 11, 2022. She serves as General Manager at Daan Gene Co., Ltd. She served as Deputy General Manager at Daan Gene Co., Ltd.since...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Luo Huang	GM & Director	2.3yrs	CN¥5.97m	Veri yok
Bin Zhang	Deputy GM	5.5yrs	CN¥5.34m	Veri yok
Zhengfu Zhu	Independent Director	2.4yrs	CN¥70.90k	Veri yok
Li Qiang Huang	Supervisor	no data	Veri yok	Veri yok
Dianhan Wei	Vice Chairman Of the Board	3.7yrs	Veri yok	Veri yok
Wanyu Zhu	Chairman of the Supervisory Board	3.7yrs	Veri yok	Veri yok
Teng Hu	Supervisor	3.7yrs	Veri yok	Veri yok
Qian Long	Director	2.4yrs	Veri yok	Veri yok
Xiaoping Chen	Supervisor	2.4yrs	Veri yok	Veri yok
Yunhai Ji	Independent Director	2.4yrs	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

47.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002030 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Daan Gene Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Daan Gene Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Insufficient new directors

Insufficient new directors

Daan Gene Co., Ltd., Annual General Meeting, Apr 20, 2022

Da an Gene Co., Ltd. of Sun Yat-Sen University Announces Executive Changes

Recent updates

Daan Gene Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0.27 profit in 2Q 2023)

Daan Gene Co., Ltd. (SZSE:002030) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

New minor risk - Share price stability

Daan Gene Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Dividend reduced to CN¥0.015

Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2023, Payable on 14 June 2024

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

First quarter 2024 earnings released: CN¥0.26 loss per share (vs CN¥0.026 profit in 1Q 2023)

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.075 (vs CN¥3.86 in FY 2022)

Daan Gene Co., Ltd., Annual General Meeting, Apr 19, 2024

Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)

Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

Now 20% overvalued

Daan Gene Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: CN¥0.035 loss per share (vs CN¥0.94 profit in 3Q 2022)

Daan Gene Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

New major risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥1.36 in 2Q 2022)

Less than half of directors are independent

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 13, 2023

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings released: EPS: CN¥3.95 (vs CN¥2.58 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.94 (vs CN¥0.66 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.36 (vs CN¥0.33 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.34 (vs CN¥0.33 in 2Q 2021)

Insufficient new directors

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of CN¥1.11 per share

Daan Gene Co., Ltd. Proposes Final Cash Dividend on A Shares for the Year 2021, Payable on May 9, 2022

Insufficient new directors

Daan Gene Co., Ltd. Approves Final Dividend for the Year 2021

Daan Gene Co., Ltd., Annual General Meeting, Apr 20, 2022

Daan Gene Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.66 (vs CN¥0.54 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Da An Gene Co., Ltd. of Sun Yat-Sen University Announces Final Dividend Implementation Plan (A Shares) for 2020, Payable on 19 May 2021

First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.21 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.77 (vs CN¥0.10 in FY 2019)

New 90-day low: CN¥29.03

Da an Gene Co., Ltd. of Sun Yat-Sen University Announces Executive Changes

Da An Gene Co., Ltd. of Sun Yat-Sen University to Report Fiscal Year 2020 Results on Mar 31, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.15

New 90-day low: CN¥31.98

Third quarter 2020 earnings released: EPS CN¥0.86

First half earnings released

First half earnings released

Da An Gene Co., Ltd. of Sun Yat-Sen University to Report First Half, 2020 Results on Aug 29, 2020

New 90-day high - CN¥40.83

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş